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ABSTRACT: 
The traditional methods for mining foods for bioactive peptides are tedious and long. Similar 
to the drug industry, the length of time to identify and deliver a commercial health ingredient 
that reduces disease symptoms can take anything between 5 to 10 years. Reducing this time 
and effort is  crucial in  order to  create new commercially viable products  with  clear and 
important  health  benefits.  In  the  past  few  years,  bioinformatics,  the  science  that  brings 
together fast computational biology, and efficient genome mining, is appearing as the long 
awaited solution  to  this problem. By quickly  mining food genomes for characteristics of 
certain food therapeutic ingredients, researchers can potentially find new ones in a matter of a 
few weeks. Yet, surprisingly, very little success has been achieved so far using bioinformatics 
in mining for food bioactives. 
The absence of food specific bioinformatic mining tools, the slow integration of both 
experimental  mining  and  bioinformatics,  and  the  important  difference  between  different 
experimental platforms are some of the reasons for the slow progress of bioinformatics in the 
field of functional food and more specifically in bioactive peptide discovery. 
In this paper I discuss some methods that could be easily translated, using a rational 
peptide bioinformatics design, to food bioactive peptide mining. I highlight the need for an 
integrated food peptide database. I also discuss how to better integrate experimental work 
with bioinformatics in order to improve the mining of food for bioactive peptides, therefore 
achieving a higher success rates. 
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INTRODUCTION: 
Food fermentation is used as a means to create food products with different or better taste, 
different functional properties, or with therapeutic qualities that otherwise are absent in the 
initial  food.  Human  consumption  of  fermented  food  is  an  ancient  practice  however  it  is Functional Foods in Health and Disease 2012, 2(10):325-338                                                    Page 326 of 338 
 
estimated that it began with the creation of cheese over 8,000 years ago. One of the major 
changes that fermentation can bring to food is hydrolyzing the food-proteins into smaller 
fragments, known as peptides. Some of these peptides have been shown to have a relevant 
impact on human health. For example bioactive peptides from various food sources have 
been shown to lower blood pressure, broccoli, egg, milk, meat, wheat, soy, and fish . Some 
peptides found in milk are anti-microbial, a similar functionality is also found in egg . 
I have witnessed in the past decade a shift in public awareness towards how certain 
elements  contained  in  food  can  enhance  ones  health  and  therefore  reduce  the  need  for 
artificial drugs. This has in turn alerted food companies to an attractive new market segment. 
This has meant that important research has been dedicated by the food industry to mining 
food  with  the  aim  of  developing  functional  foods,  such  as  products  containing  bioactive 
peptides. 
The traditional way of finding these bioactive peptides is a very long and a tedious 
process. Very often this process includes random digestion of food followed by experimental 
testing  of  hundreds  of  versions  of  a  hydrolysate.  But  the  most  tedious  part  is  then  to 
determine  the  bioactive  set  of  peptides  that  are  presenting  the  activity  within  the  active 
hydrolysates. The time and cost associated with this more traditional and purely experimental 
approach  results  in  a  small  number  of  commercial  products  with  bioactive  ingredients. 
Indeed,  less  than  20  food-peptide  based  products  are  commercially  available  (see    for  a 
detailed table about commercially available peptides), some of these include Calpis AMEEL 
S  (Japan)  and  Calpico  with  a  hypertensive  effect.  Davisco  also  created  BioPURE-GMP, 
which  is  a  peptide  mixture  with  anticariogenic,  antimicrobial  and  antithrombotic  health 
benefits.  Another  example  is  the  Glutamin  peptide  by  DMV,  which  carries  an 
immunomodulatory activity. 
Because of the above, more time, money and effort is being spent trying to detect novel 
bioactive  elements  in  food.  This  shift  has  been  accompanied  with  an  expansion  of 
nutraceutical and functional food research. The development of high throughput methods and 
techniques such as  mass-spectrometry is  resulting in  tremendous amounts  of data. Mass-
spectrometry  has  been  used  for  example  to  investigate  the  types  of  peptides  found  in  a 
hydrolysate. As a result of the slow experimental route, bioinformatics was introduced as the 
solution to quickly mine for bioactive peptides in food. Indeed this seems like an obvious 
idea given the dramatic scientific leap that bioinformatics allowed the drug industry to take 
over the last two decades.  
However,  the  emergence  of  bioinformatics  in  food  research  has  not  been 
straightforward and to date very few results have been delivered. There are many reasons to 
explain the slow success rate of bioinformatics in food bioactive peptide mining, but three 
major  ones  are  worth  mentioning.  First,  it  is  not  straightforward  to  translate  the  tools 
developed in bioinformatics in the drugs industry to mining for bioactive peptides in food. 
The  drug  industry  has  very  different  pressure  to  that  of  the  food  industry.  The  role  of 
pharmacy is to find new drugs whatever the cost and time. In contrast it is only recently that 
the food industry is realizing that functional bioactive food is the food of the future and may 
be  worth  the  investment  to  deliver  products  for  this  market.  However  this  is  still  not  a 
necessity, but rather an adaptation to a growing market need and mainly a future requirement. 
So while drug companies have always walked in parallel with state of the art technology and 
science, this is not the case for the food industry that needs to not only catch up in food 
mining but in the related general science in this area. Secondly, most of the bioinformatic Functional Foods in Health and Disease 2012, 2(10):325-338                                                    Page 327 of 338 
 
tools used in drug discovery is based on drug docking of structurally defined molecules, 
while, most of the bioactive peptides are short and thus hard to identify a structure that they 
will  adopt  outside  the  full  protein.  This  shows  that  new  bioinformatics  tools  need  to  be 
developed to meet the special requirements of mining for food bioactives as opposed to just 
translating  the  drug  mining  tools.  Finally,  there  is  very  slow  integration  of  both, 
experimental, and the in-silico food mining research. While there is pressure in the drug 
industry to adopt consensus methods and have worldwide databases, it is not the case for the 
food industry, where many of the methods are very different from lab to lab, and thus hard to 
find a generic consensus or structure. This is shown by the absence of databases for bioactive 
peptides widely used by the food industry and academics. 
The purpose of this review is to provide a possible set of bioinformatic methods that 
could be used to aid food research and industry with bioactive peptide mining. Here again, 
because of the lack of literature on the trial and error of these methods it is hard to quantify 
their success rate. But I do explain how some would have been successful in detecting known 
bioactive peptides. The focus will also be to highlight the need for a worldwide database that 
food research can update and consult on a daily basis regarding food bioactive peptides. In 
particular  I  will  discuss  how  computational  biology  can  be  integrated  with  experimental 
methods in the most efficient way to increase the yield of new bioactive peptides found in 
food. 
 
Techniques used to find bioactive peptides:  
I illustrate here different methods some of which have been successfully used to find new 
bioactive  peptides.  Most  of  these  methods  are  bioinformatic  based,  or  could  be  easily 
translated into systematic bioinformatic approach. Although most of these approaches were 
not used on food, they have great potential in finding new bioactive peptides in food. 
 
Method 1: Evolutionary conservation may play a key role in identifying new food bioactive 
peptides for some diseases 
Edwards and coauthors were interested in finding new bioactive peptides that showed a 
significant effect on human platelet function . This work represents a good example whereby 
the initial mining is performed using bioinformatics, which allowed the team to focus on a 
small number of candidates that are most likely carrying the activity of interest. The initial set 
of platelet expressed candidate proteins they had was 2900. It would have been very costly 
and lengthy to test regions of all 2900 proteins. Besides, a random selection of some proteins, 
followed by a random selection of peptides, is very unlikely to yield results. Instead, the 
authors applied a rational peptide design approach specifically targeted at juxtamembrane 
regions that were predicted to have signaling activity and could be modulators of platelet 
function. To narrow down the space of search to candidates most likely carrying the desired 
functionally the authors used bioinformatics to identify 47 candidates highly expressed trans-
membrane proteins with signatures of functionally specific residues in cytoplasmic tails or 
loops .  They  carried  out  this  using  an  evolutionary  approach  whereby  the  chosen 
peptides span residues that are strongly similar (conserved) to those in the corresponding 
proteins in other species (orthologs), but that differ from those in related human proteins 
(paralogs) .  An  example  is  illustrated  in  Figure  1-A  using  a  milk  protein  example.  The 
authors reasoned that because the functionality of platelet aggregation is crucial to the cell, 
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in a related protein that has a different function in that region. The peptides also had to lie 
within 30 amino acids of the membrane and meet certain synthesis and solubility criteria .  
This computational approach allowed the experimental biologist to test candidates that 
most likely carry this functionality rather than random candidates. The results showed that 26 
peptides have significant effect on platelet function . This significant finding would not have 
been possible without the initial bioinformatic screening. 
 
Method 2: Amino-acid composition and preference can define some diseases allowing for 
the discovery of new food bioactive peptides 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Often bioactive peptides perform a given function because of their structure and amino acid 
composition. Figure 1-B is an illustration of an example where patterns of amino acids are 
established based on amino acid preferences at certain positions for a number of peptides all 
carrying  a  similar  functionality.  For  example  Jianping  Wu  et  coauthors  carried  out  an 
interesting study to examine the quantitative structure−activity relationships of angiotensin I-
converting enzyme (ACE) inhibitory peptides. These peptides have a blood pressure lowering 
effect, and are thus interesting for the cardiovascular functional food community. Using a 
computational approach partial least squares regression they found that di-peptides carrying 
an ACE inhibitory function preferred residues with bulky side chains as well as hydrophobic 
 
Figure 1. Representation of three different methods used to find new bioactive peptides. 
A. Alignment of the region 128-143 of bovine -S1-casein between related species. The blue 
box surrounds the region that is conserved relatively to the surrounding region in the protein. 
B. Mimicking a region of interaction between two proteins, the new peptides can inhibit the 
interaction  of  both  proteins.  C.  Example  of  amino  acid  preference  underlining  the 
functionality of a set of peptides shown to reduce a given disease.  For the figure purpose I 
chose to only show 4 peptides, numerous other peptides are represented by dots.  
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side chains.  For tri-peptides, the most favorable residues for the  carboxyl terminus  were 
aromatic amino acids, positively charged amino acids were preferred for the middle position, 
and hydrophobic amino acids were preferred for the amino terminus. These patterns allowed 
the authors to mine for peptides that carry similar structures. They mined pea, bovine milk, 
and  soybean  proteins  and  predicted  7  new  biaoctive  peptides  (3  di-peptides,  and  4  try-
peptides) that are likely carrying an ACE-inhibition effect.  
 
Method 3: Mimicking a Binding Partner to discover new bioactive peptides:  
In this paragraph I describe an interesting approach that has been very effective in the drug 
industry. This mimicking approach, illustrated in Figure 1-C, uses a reasoning that can easily 
be translated into a bioinformatics approach to mine for bioactive peptides in food.  
Protein-protein interactions are difficult to inhibit. Thus it is not evident to expect that a 
peptide may inhibit a Protein-protein interaction by mimicking a region of the protein where 
the interaction takes place. Indeed peptides can be small and one may expect low structure 
conservation relative to the protein. Interestingly and unexpectedly, a study carried out on 
protein kinase C (PKC) has demonstrated that competitive inhibition of this protein by a 
peptide that mimics the interaction region of this protein is possible. 
PKC are a family of serine/threonine kinases, which are involved in many signaling 
events. These enzymes are associated with many diseases including cancer, diabetes, heart 
attack, stroke, and heart failure. Because of this association great attention has been made to 
generating PKC isoenzyme-selective inhibitors that target the active enzyme. This approach 
has been - to say the least- challenging. 
This all started with the observations made by Alistair Aitken that 14-3-3, a protein he 
found to inhibit PKC , and annexin I, a protein found by Mochly-Rosen and co-workers to 
bind  βPKC  ,  share  a  12-amino-acid  sequence  of  homology  triggered  an  interesting  idea. 
Mochly-Rosen and co-workers, reasoned that because these two unrelated proteins share this 
region, and that both bind to PKC, this region may mediate the binding of both proteins to 
PKC. 
Mochly-Rosen  and  co-workers,  decided  to  investigate  the  action  of  this  peptide 
(consequently named peptide I) on PKC interaction with RACK and annexin I. The results 
showed  that  consequently  peptide  I  prevented  the  access  of  the  active  enzyme  to  its 
substrates, leading to inhibition of the downstream physiological responses (the anchoring of 
activated PKC to RACK is inhibited). 
This approach has since been used in many other studies. From our perspective it is 
easy to see how this approach could be computationally applied to thousands of interacting 
proteins  to  yield  possible  common  regions  responsible  for  these  interactions.  This 
competitive inhibition of PKC by a region that mimics its interaction with other proteins is 
potentially a good method to identify new functional food peptides. The idea is that unrelated 
protein interacting with the same protein may share a common region allowing this binding to 
occur. In other words, a pathway may be promoted or inhibited via these mimicking peptides. 
Another similar example of the presence of a similar sequence in unrelated proteins is 
the presence of KEN-box motifs in unrelated proteins. Indeed these motifs are used by the 
Anaphase-Promoting Complex (APC/C), which is a ubiquitin ligase complex that plays a 
major role in regulation of signal transduction, to mark cell cycle proteins for degradation by 
the 26S proteasome. Using a computational approach Sushama Michael and co-authors found 
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disorder  and  evolutionary  conservation  to  separate  between  possibly  functional  and  non-
functional KEN motifs. Indeed intrinsic protein disorder has been shown to be rich in motifs 
and evolves similarly between proteins of the same complex. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Method 4: Positive selection may play a key role in identifying new bioactive peptides in 
food proteins: 
When  I  and  Prof  Denis  Shields  investigated  the  significant  shift  in  charge  and 
isoelectric point of milk proteins between different species we realized that an important 
contributor to these shifts are the significant differences between amino acids composition at 
certain positions in different mammalian milk proteins . Many of these residues we predicted 
to be under positive selection. But a major side observation we had made from these results is 
the overlap between bioactive peptides, found in bovine milk casein, and residues that are 
under positive Darwinian selection (this is illustrated in Figure 4 of). Most of the known 
literature peptides in -casein seem to either overlap over these residues or be adjacent to 
them in the parent sequence. One of the results of this study is that positive selection seems to 
be an indicator for the presence of a bioactive peptide. In other words, residues in bioactive 
 
Figure  2.  Schematic  representation  of  a  centralized  database  for  functional  food 
peptides. A user can either add information into the database by giving the activity they 
investigated, the peptides they tested, the assay they used, and the positive or negative results 
they found. DB stands for database, and aa for amino acid. Functional Foods in Health and Disease 2012, 2(10):325-338                                                    Page 331 of 338 
 
peptides  or  surrounding  them  seem  to  be  under  fast  sequence  evolution,  perhaps  the 
consequence  of  a  species  adaptation  to  varying  needs  in  different  species.  It  would  be 
interesting  in  further  studies  to  see  if  this  observation  extends  to  other  known  bioactive 
peptides. 
The above seems to contradict the evolutionary conservation method used by Edwards 
and  coworkers  to  define  novel  platelet  aggregation  peptides.  It  is  expected  that  some 
functions are widely needed in many species and are expected to be conserved, while other 
are more species specific, for example anti-opioid function seems to be an activity that is not 
conserved (casoxin-A; ), and thus species specific. Thus, both methods are not a contradiction 
per se but the result of the different functionalities carried by a bioactive peptide that may 
need to be conserved or not.  
A possible way for finding bioactives in a protein sequence using this method is to 
investigate  the  residues  under  positive  selection  and  test  the  peptide  that  contain  these 
selected residues. Delineating the peptide will be somewhat challenging and would possibly 
require a few trials and errors. 
 
Possible success using the methods above: 
The mechanisms of action of many of the commercial or literature known food bioactive 
peptides remain unknown. Thus it is hard to measure the success rate of approach 1 and 3 on 
re-discovering these known peptides, as both these methods require a particular knowledge of 
what pathways or interactions one wants to target. However using method 2, which only 
depends on the sequence, would have discovered the tri-peptide “IKW” an ACE-inhibitory 
peptide. Furthermore using method 4, which also depends on the protein sequence would 
have allowed us to discover the Opioid antagonist Casoxin A and C in casein, and at least 
highlight another Opioid antagonist in -casein namely Casoxin B , and the antithrombotic 
peptide Casoplatelin also found in -casein. 
Method 1 yielded positive results most likely because the assayed effect  -a platelet 
response- is an inherent part of the native protein function. The use of this method without 
some prior knowledge of the disease targets or protein interactions required to yield a positive 
effect on the disease under consideration will be of ineffective. Once this bigger picture is set 
for a given species such as human, mining for peptides in the homologous proteins in plants 
of their counter parts in human becomes feasible. And method 1 would potentially lead to 
significant results 
Similarly  to  method  1,  the  use  of  method  3  will  require  prior  knowledge  of  what 
interaction we would like to inhibit. Once this knowledge is established the identification of 
peptides in food proteins that would mimic the interacting protein becomes possible. 
 
Other existing methods to predict functional regions in a protein sequence. 
There  are  some  other  methods  to  predict  functional  regions  in  protein  sequences,  these 
include searches for Molecular Recognition Features (MoRFs) and various short linear motif 
(SLiMs).  But  from  my  own  experience  these  predictors  have  failed  to  predict  novel, 
functional, and commercially viable bioactive peptides. A possible explanation for this is that 
SLiMs for example are usually found in disordered regions of a protein. It has been shown 
for example that differences between disordered regions in duplicates can cause functional 
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regions  happen  to  also  be  post-translationally  modified  regions,  phosphorylated  and 
glycolsylated. This fact makes it very hard for enzymes to reach and cleave potential peptides 
in these regions. So although these disordered sequences may have peptides, they will be 
impossible to reach easily without heavily modifying or breaking the protein, something the 
food  industry  will  not  be  too  keen  on,  for  many  reasons  one  of  which  is  taste.  Further 
research in this area will allow a better understanding of the relationship –if any- between 
MoRFs and/or SLiMs and the bioactive food peptides. 
 
A worldwide database for bioactive peptides: Includes information about peptides that 
presented an activity and ones that did not present any activity: 
In  order  to  systematically  develop  bioinformatic  methods  to  analyze,  predict  bioactive 
peptides,  and  aid  researchers  in  discovering  new  ones  it  is  important  to  create  a  central 
database (Figure 2). This database will centralize all available information about peptides that 
have been tested on an assay. The type of assay should be predefined in the database, where 
the user will only need to select the assay they have used. This is to minimize results that are 
not conformational to known and widely accepted assays. What is crucial for any predictions 
is the use of published and unpublished data. Many peptides have been tested but yielded 
negative  results  in  some  assays.  This  unwanted  data  is  currently  an  unused  mine  of 
information.  Indeed,  these  negative  results  are  as  crucial  as  is  the  information  about  the 
peptides  that  yield  positive  results.  One  may  not  observe  any  commonalities  between 
peptides that have shown a positive action on an assay in relation to a disease, but contrasting 
this information with peptides that have shown negative effects in the same disease related 
assays may lead to discovering the key characteristics needed for the functionality of these 
peptides. 
This central database will not only contain food related bioactive peptides, but will 
integrate with all peptide databases resources to enrich the set of peptides for each disease 
thus increasing the prediction power for novel bioactive peptide (Figure 2). 
As mentioned above, there seems to be no clear-cut and general method for discovering 
novel bioactive peptides. Some methods may be good at predicting bioactive peptides for a 
certain disease but do not work on another. For this reason, it is important to implement all 
these  different  methods  automatically  on  each  group  of  peptides  (Figure  2;  a  group  of 
peptides is defined as a set of peptides that share a common characteristics such as they all 
lower cholesterol). The data that is constantly updated in the central database will be passed 
through different bioinformatic methods, such as the ones described above. For example, an 
amino  acid  preference  matrix  will  be  constructed  for  each  disease.  An  evolutionary 
characterization of each peptide, whereby the closest homologs of the proteins that contains 
these peptides are aligned to determine signals of positive selection, which seems to be an 
indicator for the presence of a bioactive peptide (Figure 1-b).  
 
The  bigger  picture:  effectively  integrating  bioinformatics  and  experimental  work  to 
mine for new food bioactive peptides.  
Here I recommend a process for effectively discovering novel bioactive peptides. The aim of 
these  approaches  is  to  accelerate  the  tie  between  finding  an  active  hydrolysate  and 
discovering  the  peptides  responsible  for  this  activity.  This  process  will  integrate  three 
different approaches as outlined in Figure 3 and discussed in more detail below.  
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is the generation of digested food or hydrolysates (Figure 3, top panel). Corn for example will 
undergo digestion with a combination of different enzymes, or different bacterial organisms 
under different conditions (pH, temperature, time in contact with enzyme). This method is 
purely  experimental  and  will  produce  hundreds  of  different  hydrolysates  that  are  then 
experimentally tested in different assays representing different diseases. 
The aim of any organization conducting this  study is  the commercialization of the 
positive  results.  A  positive  hydrolysate  that  actively  lowers  a  disease  can  either  be 
commercialized as is, in which case the claims on this product are limited. Or it can be 
further  mined  to  find  the  bioactive  element(s)  and  thus  improve  the  claim.  Using  a 
computational  approach  at  this  point  is  crucial  in  handling  these  amounts  of  data  and 
predicting what fragments are the most likely bioactive in each positive hydrolysate. Indeed a 
purely experimental approach would result in years of trial and error, a luxury that industry 
can’t indulge in. Some approaches can then be adopted in bioinformatics to narrow down the 
huge data to a small fraction of candidates likely carrying the required bioactivity. 
 
First approach – Peptides in common between hydrolysates performing similar functions 
can identify the key players in each hydrolysate: 
We are in the situation where many hydrolysates have been tested, some of which 
present a positive action that is sought after. For example some hydrolysates may have been 
tested  for  their  effect  on  cholesterol  and  shown  to  lower  cholesterol.  The  question  then 
becomes, which peptides are the most likely carriers of this functionality? If a number of 
hydrolysates  have been  found to perform similar actions  on a  given disease, their mass-
spectrometry  data  (consisting  of  the  lists  of  peptide  sequences  that  are  found  in  these 
hydrolysates) can be searched for sequences that are common between all the hydrolysates. It 
is indeed the common segments that are the most likely carriers of this bioactivity. This step 
will help reduce the number of candidate peptides to a smaller fraction.  
Two likely scenarios can occur. Firstly, the list of candidate peptides found using this 
approach is small enough to synthesize and test each sequence individually in order to expose 
the  true  bioactive  peptide(s).  Secondly,  the  list  of  peptides  is  too  large  to  realistically 
synthesize and test all of them. In this situation a further computational approach is needed to 
segregate the different peptides, and to yield an even smaller set. This is where the integration 
of different bioinformatic methods, some of which are illustrated above, will be useful in 
reducing the data. 
 
Second approach – Integration of different bioinformatic methods to find novel bioactive 
peptides: 
This second approach is used to further reduce the set of candidate peptides found 
using  the  1st  approach.  The  overall  strategy  of  detecting  new  bioactive  elements  cannot 
succeed without further understanding the characteristics of what one is looking for. One 
cannot search a hydrolysate aimlessly without a goal. The in-silico prediction of peptides 
should run in parallel to any hydrolysate testing and mining.  Functional Foods in Health and Disease 2012, 2(10):325-338                                                    Page 334 of 338 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As discussed above, there are many methods that can be integrated together to yield a better 
predictive  power  for  bioactivity.  Some  of  these  were  discussed  above,  these  include  the 
evolutionary approach, the amino acid composition preference approach, the mimicking and 
competition approach. Also as discussed above, some methods may have a higher predictive 
power on certain disease. This is why it is important to integrate all of these to extract the 
most information. It is in this second approach where the need for a worldwide functional 
peptide database is highlighted. Indeed the candidates from the first approach can be used as 
a query against this database, which will perform all the methods discussed above (together 
with  future  methods)  and  will  provide  information  on  how  likely  each  peptide  is  to  be 
bioactive in a given assay. This of course can only be provided when sufficient information is 
collected  in  the  database.  The  more  information  we  find  in  the  literature  the  better  our 
   
Figure  3.  Integrating  experimental  results  with  bioinformatics  to  accelerate  bioactive 
detection in food.  Functional Foods in Health and Disease 2012, 2(10):325-338                                                    Page 335 of 338 
 
predictive power becomes.  
So far these approaches only deal with peptides visible in mass-spectrometry. In many 
cases the peptides found by mass-spectrometry only cover very little of the parent proteins 
they derive from. It is not unreasonable to suggest that much of the bioactivity may be in 
regions that are not seen in mass-spectrometry and these regions should also be searched. 
 
Third approach – Filling the gaps of mass-spectrometry can allow the identification of new 
bioactive peptides that otherwise would not be identified 
This third approach is also computationally oriented (Figure 3). The initial aim of this 
approach is filling the gaps of mass-spectrometry. Although mass-spectrometry has provided 
a great source of information of the fragments present in the hydrolysate, it is often limited. 
Searching computationally for bioactive fragments in some hydrolysates with poor coverage 
is limited. A way to tackle this issue is by computationally digesting the proteins of the initial 
food of interest, corn proteins for example. Knowing the enzymes that have been used to 
generate the hydrolysate one can computationally predict where these enzymes will cleave in 
the  areas  that  Mass-spectrometry  failed  to  see.  Bear  in  mind  that  prediction  of  enzyme 
digestion can be tricky, especially in regions of post-translational modification. An enzyme 
may be predicted to cleave a residue, but in reality this residue is glycosylated, in which case 
the sugars may prevent the enzyme from cleaving at that position. Nonetheless this approach 
is currently the best way to predict bioactivity in the hidden regions of mass-spectrometry. 
The peptides found in this approach can be put through approach 1 and 2 to get a final 
small set of candidate peptides ready for experimental validation. 
 
CONCLUSION: 
The integration of bioinformatics with food mining has so far been slow. Many issues are 
hampering the advancement in this field. Some of these include absence of bioinformatic 
mining tools specifically coded for the food research needs; the insufficient systemization of 
experimental assay testing of bioactive peptides; a rich central functional food database that 
bioinformatics can mine. 
I described a few successful methods that have found novel bioactive peptides (Figure 
1).  These  methods  have  been  used  on  a  selection  of  different  questions,  and  have  great 
potential in discovering bioactive peptide in the functional food area (Figure 1). 
The diversity of the methods indicates that multiple approaches  are needed to  find 
bioactive peptides. Some methods work well for a given disease, while they do not on others. 
A  combination  of  different  bioinformatic  methods  is  needed  to  mine  food  for  bioactive 
peptides (Figure 1).  
Finally, integrating both bioinformatic and experimental biology is the only way that 
saves both money and time in discovering new bioactive peptides (Figure 3). I discuss a 
process that I think will achieve a great yield in mining for new bioactive peptides I food 
(Figure 3). For this reason, a centralized database accessible by all food laboratories, and 
containing published and unpublished data is necessary to increase the predictive power of 
bioinformatics  in  mining  food  (Figure  2).  This  database  will  implement  a  variety  of 
approaches  found  to  have  been  successful  in  mining  for  bioactive  peptides,  as  the  ones 
mentioned in the text and shown in Figure 1. Functional Foods in Health and Disease 2012, 2(10):325-338                                                    Page 336 of 338 
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